Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
CADENCE: Docetaxel and Carboplatin in TNBC
NCT02547987Phase 2Active, not recruiting
- Sponsor
- Mothaffar Rimawi
- Start
- Nov 2015
- Primary completion
- Jun 2019
- Modality
- DNA Intercalators/Alkylators
- Countries
- 1
01
Overview
A Phase 2 trial of carboplatin, docetaxel in triple-negative breast cancer (TNBC), sponsored by Mothaffar Rimawi. Started Nov 2015; status: active, not recruiting.
02
Drugs
carboplatindocetaxel
03
Conditions
triple-negative breast cancer (TNBC)
Beyond the preview
Go deeper on NCT02547987.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT02547987.